Navigation Links
Anthera Announces First Quarter 2013 Financial Report and Conference Call
Date:5/3/2013

HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13th. Anthera will host a Corporate Update conference call on May 20th, 2013.

Conference Call Access:
Date:   Monday, May 20th, 2013
Time:   5:00 pm Eastern Time

Domestic Dial-in:        (877)312-8807
International Dial-in:   (253)237-1190
Conference ID:           64577060

To access the 24-hour audio replay, U.S. and Canadian participants may dial (855)859-2056; international participants may dial (404)537-3406.  The conference ID for the replay is 64577060. The audio replay will be available until May 27th, 2013. 

About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510-856-5598.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCalls Microscope
2. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
3. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
4. Anthera to Report Second Quarter 2012 Financial Results
5. Life Technologies Announces First Quarter 2013 Results
6. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. BioLife Solutions Announces License Agreement
9. PRIM&R Announces Longtime Leader to Step Down
10. MiMedx Announces Record First Quarter 2013 Results
11. ViroPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Myriant Corporation, a global ... a distribution agreement with Azelis Group, a specialty ... bio-succinic acid in the Nordics, Benelux, France, Iberia, ... in the industrial and base chemicals markets. , ... a far-reaching chemical portfolio with extensive distribution networks ...
(Date:9/2/2014)... 2, 2014  Synthetic Biologics, Inc. (NYSE MKT: ... drug candidates targeting specific pathogens that cause serious ... its final preclinical toxicology study of SYN-004. Per ... bridging study was required to move the Company,s ... the devastating effects of Clostridium difficile (C. ...
(Date:9/2/2014)... Victoria, Australia (PRWEB) September 02, 2014 ... provide a cure for chronic tinnitus are seeking support ... run on the Indiegogo platform ( http://igg.me/at/tinaway ), was ... to be a therapeutic ‘mHealth’ app and is based ... brainchild of a team of biomedical and software engineers, ...
(Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... Goal Is to Lower the Cost of Genome ... Information Universally Available for Routine Medical Care-PHILADELPHIA, Feb. ... whole genome imaging and analysis platforms for biomedical ... that its low-cost nanofluidic genome analysis technology, along ...
... 24 Environment of Care managers can ... achieve and maintain their organization,s environment of care ... series of brief, web-based audio interviews with EC experts ... or download at http://www.eheinc.com/ec_bits.htm feature expert advice ...
... ABBOTT PARK, Ill., Feb. 24 Abbott ( ... Healthcare Conference on Tuesday, March 10, 2009. Thomas ... officer, will make a formal presentation on the company ... the presentation will be accessible through Abbott,s Investor Relations ...
Cached Biology Technology:BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 2BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 3Web-based Audio Interviews Keep Environment of Care Managers Up-to-Date on Key EC Compliance Issues 2
(Date:9/2/2014)... issue of The FASEB Journal , ... the leading cause of blindness in adults, diabetic ... advance involves quantifying the early molecular changes caused ... Using new probes developed by scientists, they were ... diabetic retinopathy. , "My goal is to establish ...
(Date:9/2/2014)... D.C., September 2, 2014 A study published ... Journal of the American Academy of Child and ... diagnosed with a psychiatric diagnosis had an increased ... to antipsychotics. , Using data from the nationwide ... Dr. Ren Ernst Nielsen, Psychiatry, Aalborg University Hospital, ...
(Date:9/2/2014)... Bavaria, the Tithonian Konservat-Lagersttte of lithographic limestone is ... of emblematic fossils from that area (for example, ... found fossil insects in the French equivalent of ... species representing the oldest known water treader. , ... Bavarian outcrops, fewer fossils have been obtained from ...
Breaking Biology News(10 mins):Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2Risk of diabetes in children and adolescents exposed to antipsychotics 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... perennially covered in ice. It is exposed to severe ... and, during the winter, 24-hour darkness. But, for the ... To study them, Dr. Rachel Morgan-Kiss from the University ... to sample the ice-covered lake. The article describing her ...
... the most valuable possessions in the most secure safes, ... at the European Molecular Biology Laboratory,s European Bioinformatics Institute ... Nature , shows that bacteria have evolved a ... reducing the risk of self-destruction. The findings answer a ...
... of Gothenburg, Sweden, have identified the genetic variations ... in Nature Genetics and involving leading researchers ... facts that women with a higher proportion of genetic ... percent increased fracture risk. Osteoporosis is a common ...
Cached Biology News:Research on carbon-consuming life-forms in Antarctica published in JoVE 2A matter of priorities 2Scientists have discovered genes that increase the risk of osteoporosis and fractures 2
Extra Large bottle for hybridization 300 x 70mm...
Request Info...
... Microtube Rotor is TWO ROTORS in ONE! ... You can spin both 1.5 - ... polypropylene rotor design provides excellent chemical resistance ... rotors are fully compatible with common decontamination ...
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
Biology Products: